Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Align Technology, Inc. stock logo
ALGN
Align Technology
$198.51
+0.8%
$181.73
$141.74
$263.24
$14.31B1.63911,224 shs10,621 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$79.72
+0.1%
$83.51
$73.11
$126.89
$5.50B0.121.02 million shs7,719 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$252.24
+1.0%
$271.10
$148.00
$310.00
$9.74B0.47450,882 shs2,329 shs
Stryker Corporation stock logo
SYK
Stryker
$393.03
+0.3%
$381.77
$314.93
$406.19
$149.79B0.911.34 million shs22,064 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Align Technology, Inc. stock logo
ALGN
Align Technology
+1.39%+5.26%+10.35%+27.71%-17.84%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.25%-1.15%+3.23%-18.09%+1.43%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.66%-1.50%-2.74%-8.57%+41.79%
Stryker Corporation stock logo
SYK
Stryker
-1.11%-0.10%+2.94%+6.48%+17.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Align Technology, Inc. stock logo
ALGN
Align Technology
4.6251 of 5 stars
3.34.00.03.83.51.71.3
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.457 of 5 stars
3.51.00.04.22.22.51.9
Penumbra, Inc. stock logo
PEN
Penumbra
4.7337 of 5 stars
3.43.00.03.73.42.51.9
Stryker Corporation stock logo
SYK
Stryker
4.6361 of 5 stars
2.43.03.34.22.92.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Align Technology, Inc. stock logo
ALGN
Align Technology
2.67
Moderate Buy$241.2521.53% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$130.5063.71% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4019.89% Upside
Stryker Corporation stock logo
SYK
Stryker
2.79
Moderate Buy$427.308.72% Upside

Current Analyst Ratings Breakdown

Latest SYK, LNTH, PEN, and ALGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
5/22/2025
Stryker Corporation stock logo
SYK
Stryker
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$443.00 ➝ $455.00
5/8/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $117.00
5/5/2025
Stryker Corporation stock logo
SYK
Stryker
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$450.00
5/5/2025
Stryker Corporation stock logo
SYK
Stryker
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$390.00 ➝ $400.00
5/5/2025
Stryker Corporation stock logo
SYK
Stryker
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/2/2025
Stryker Corporation stock logo
SYK
Stryker
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$405.00 ➝ $456.00
5/2/2025
Stryker Corporation stock logo
SYK
Stryker
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$400.00 ➝ $390.00
5/1/2025
Align Technology, Inc. stock logo
ALGN
Align Technology
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$255.00 ➝ $246.00
5/1/2025
Align Technology, Inc. stock logo
ALGN
Align Technology
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$235.00 ➝ $250.00
5/1/2025
Align Technology, Inc. stock logo
ALGN
Align Technology
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$165.00 ➝ $200.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Align Technology, Inc. stock logo
ALGN
Align Technology
$4.00B3.60$9.19 per share21.61$51.60 per share3.85
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.60$7.12 per share11.19$15.65 per share5.09
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.18$2.90 per share86.84$29.99 per share8.41
Stryker Corporation stock logo
SYK
Stryker
$22.60B6.64$14.94 per share26.30$54.13 per share7.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Align Technology, Inc. stock logo
ALGN
Align Technology
$421.36M$5.4935.9722.182.0610.29%13.52%8.36%7/30/2025 (Confirmed)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5222.5912.63N/A16.55%36.99%20.55%7/30/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$1.06237.1850.352.233.41%11.14%8.40%7/29/2025 (Estimated)
Stryker Corporation stock logo
SYK
Stryker
$2.99B$7.4053.0326.502.9912.31%23.74%11.25%7/29/2025 (Estimated)

Latest SYK, LNTH, PEN, and ALGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Align Technology, Inc. stock logo
ALGN
Align Technology
$2.57N/AN/AN/A$1.06 billionN/A
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81N/AN/AN/A$327.37 millionN/A
7/29/2025Q2 2025
Stryker Corporation stock logo
SYK
Stryker
$3.06N/AN/AN/A$5.92 billionN/A
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
5/1/2025Q1 2025
Stryker Corporation stock logo
SYK
Stryker
$2.73$2.84+$0.11$1.69$5.68 billion$5.87 billion
4/30/2025Q1 2025
Align Technology, Inc. stock logo
ALGN
Align Technology
$2.00$2.13+$0.13$1.27$977.90 million$979.26 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Align Technology, Inc. stock logo
ALGN
Align Technology
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Stryker Corporation stock logo
SYK
Stryker
$3.360.85%N/A45.41%32 Years

Latest SYK, LNTH, PEN, and ALGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2025
Stryker Corporation stock logo
SYK
Stryker
quarterly$0.840.88%6/30/20256/30/20257/31/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Align Technology, Inc. stock logo
ALGN
Align Technology
N/A
1.21
1.08
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.30
3.68
Stryker Corporation stock logo
SYK
Stryker
0.69
1.64
1.00

Institutional Ownership

CompanyInstitutional Ownership
Align Technology, Inc. stock logo
ALGN
Align Technology
88.43%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Stryker Corporation stock logo
SYK
Stryker
77.09%

Insider Ownership

CompanyInsider Ownership
Align Technology, Inc. stock logo
ALGN
Align Technology
0.66%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Stryker Corporation stock logo
SYK
Stryker
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Align Technology, Inc. stock logo
ALGN
Align Technology
20,94572.49 million72.01 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million68.15 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50038.73 million37.10 millionOptionable
Stryker Corporation stock logo
SYK
Stryker
53,000381.69 million359.17 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Align Technology stock logo

Align Technology NASDAQ:ALGN

$198.51 +1.53 (+0.78%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth. The segment also provides Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment; and Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and orthodontists software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface designed to enhance dental consultations; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, pay per scan, and CAD/CAM software solutions. The company was incorporated in 1997 and is headquartered in Tempe, Arizona.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$79.72 +0.10 (+0.12%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Penumbra stock logo

Penumbra NYSE:PEN

$252.24 +2.50 (+1.00%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Stryker stock logo

Stryker NYSE:SYK

$393.03 +1.22 (+0.31%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.